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Abstract
The most common best management practice used to combat diseases in horses is
vaccination, which can decrease the incidence or severity of illness. However, the
duration of immunity will vary for each vaccination and must be considered for
revaccination purposes. Titer concentration, which evaluates antibodies in the blood, may
be a helpful way of determining how long an animal has immunity to a disease.
Leptospirosis, a zoonotic, bacterial disease, can result in uveitis, potentially leading to
blindness, and abortion in mares. One serovar, Leptospirosis pomona (L. pomona), is
associated with most cases of clinical disease in horses in North America. There is one
approved vaccine, specific for L. pomona, currently available for this disease. The
objective of this study was to evaluate the immune response in horses to the L. pomona
vaccine.
Forty previously unvaccinated horses from the Murray State University Equine
Center were used in this study. None had previously documented issues with uveitis or
abortion. Blood was drawn and serum removed for evaluation of leptospirosis titers.
Horses were then divided into TRT (vaccinated, n=20) or CON (not vaccinated, n=20),
and TRT horses were vaccinated for leptospirosis. Blood samples were collected from 37
(TRT n=20; CON n=17) horses 14 d post-vaccination. Horses in the TRT group received
booster vaccines 3 weeks after the first vaccination. Blood samples were again collected
from 37 horses 14 d post booster. At each collection, 20 ml of blood were collected by
jugular venipuncture into 2 red top vacutainers® tubes. Samples were centrifuged and
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serum removed within 24 hours. Serum was delivered to the Breathitt Veterinary Center
and either analyzed within 48 hours or frozen until analysis could be completed.
Descriptive statistics were used to evaluate the results.
Preliminary results showed a higher seroprevalence of L. pomona in this study
(8%, n=3 of 37) when compared to previously published research of unvaccinated horses.
Kitson-Piggot and Prescott (1987) found that only 4% of horses in Ontario had a positive
titer for L. pomona, and Fagre et al. (2020) found only a 1% incidence for the same
serovar in horses in Colorado. Given that the location for horses in the previous studies
were spread out over a larger geographical distance than the horses in this study, it is
possible that the University horses were concentrated and exposed to a greater degree
than horses in the other studies. After the initial vaccination was administered, all horses
in the TRT group showed an increase in antibody concentration which resulted in a
positive titer for each horse. Titers increased at varying rates, ranging from 1:200 to
1:25600. After receiving the booster vaccination, five TRT horses showed no change in
titer, six horses had another increase, and nine horses showed a decrease in titer
concentration. No horses showed any signs of illness related to leptospirosis during the
study. Further analysis of the results may lead to greater understanding of the equine
immune response to this vaccine.
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Literature Review
Introduction
Vaccines are given to most, or all, domesticated animals to aid in protection or
prevention of diseases. Currently, most vaccines are given on an annual basis, but studies
have led us to believe that this may not be necessary as the immunity, or the titers, can
last longer than a year with some vaccines in some animals (Moore & Glickman, 2004).
This new development in vaccination guidelines has led to more studies on vaccination
immunity length in different animals. This literature review focuses on equine
vaccinations and their uses, and the vaccine information and guidelines for leptospirosis
in equines.
Diseases
According to the Merriam-Webster dictionary, a disease is anything that impairs
the normal function of a living thing1. The Mayo Clinic states that infectious diseases are
disorders caused by organisms like bacteria, viruses, fungi, and parasites2. Common
diseases in horses include equine influenza, tetanus, and equine encephalomyelitis. A
variety of methods can be used to protect animals from diseases. This can include

1

Merriam-Webster. (n.d). Disease. In Merriam-Webster.com dictionary. Retrieved September 10, 2022,
from https://www.merriam-webster.com/dictionary/disease.
2
Mayo Clinic. (2022, February 18). Infectious diseases. Mayo Clinic.
https://www.mayoclinic.org/diseases-conditions/infectious-diseases/symptoms-causes/syc-20351173

2

biosecurity measures, such as isolation of sick animals or proper manure management, as
well as vaccinations.
What are Vaccines
A vaccination is a product that has been developed to give an animal immunity
against a disease or virus. They help to prevent or reduce the effects of certain diseases as
well as protect against transmission of zoonotic diseases. When an animal is vaccinated,
antibodies are formed to combat the pathogens simulated by the vaccine. The animal then
has what is called active immunity. Active immunity is obtained through vaccinations
and protects the animal against the disease or virus. As the animal ages and comes in
contact with these pathogens in a live situation, their body will already have the
antibodies to protect them against contracting it, or in other cases, greatly reducing the
symptoms (Scott, n.d.).
Types of Vaccines
Vaccines are currently available as modified live vaccines or inactive vaccines.
Modified live vaccinations contain live, attenuated organisms, or a weakened form of the
virus. They create an immune response in the animal that replicates the response if the
animal were to actually contract the disease. This immune response allows for the rapid
production of antibodies and gives the animal protection against the virus in the future.
Inactive vaccines contain viruses that have been exposed to inactivating agents like
formaldehyde, β-propiolactone, ethylene-imine, or thimerosal (Minke et al., 2004).
Immunogens are then extracted from the inactive virus and combined with adjuvants to
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create the vaccine. The immunogens and adjuvants stimulate the antibody production for
the virus in the animal's body. The downsides to inactive vaccines are that their antibody
production is much slower compared to the production rate when modified live vaccines
are used. Additionally, they often require boosters and do not create a strong immunity to
the virus (Minke et al., 2004).
Vaccinations can also have adverse effects on an animal. Most vaccines will
produce some kind of reaction either around the injection site or in mild clinical signs,
but this is to be expected after stimulating the immune system so strongly with the
vaccination. More severe adverse reactions can be caused from improper handling or
administering of the vaccine, contamination, allergens, and other causes. Some vaccines
have also failed to protect the animal from the disease. Vaccine failure can be caused by
things like insufficient time to develop immunity, alterations to the vaccine, host factors
preventing immunity, excessive exposure to pathogens, and other causes (Roth, 1999).
Most vaccines continue to be administered on an annual basis, while others are
given more or less frequently. Factors affecting vaccine frequency can include risk level
in the area, duration of immunity for that vaccine, the animal’s response to the vaccine,
etc. Vaccinations are classified as either core vaccines that are given every year in every
location, or risk-based vaccines that are given on an as needed basis. Equine core
vaccines include tetanus, Eastern and Western encephalomyelitis, rabies, and West Nile
virus (Desanti-Consoli et al., 2022). These diseases are core because some are incurable
and some are zoonotic, meaning they can infect other species including humans. Risk
based vaccines are given based on location and risk level (Desanti-Consoli et al., 2022).
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Some locations have a higher prevalence of diseases compared to other locations.
Additionally, some animals may be more susceptible, or at a greater risk to some
diseases. In these situations, risk-based vaccines relevant to each animal's needs and
location would be administered.
Duration of Immunity
Duration of immunity can be affected by a number of variables. Whether the
vaccine is live or inactive, the disease that the vaccine is for, and the age of the animal are
a few factors that can change the duration of immunity. For example, in dogs, immunity
from vaccinations has been shown to last up to three years for certain pathogens (Harvey
et al., 2016). Additionally, geriatric animals may have a decreased immune response to
vaccines (Harvey et al., 2016). Due to the wide number of variables that can affect the
duration of immunity, determining an accurate vaccination timeline for every horse can
be difficult. By not revaccinating every year, it can help to reduce adverse symptoms
created by vaccinations but changing vaccination intervals could leave some animals
unprotected against these diseases. Blood tests to measure the titer levels can be a way to
help determine how often a horse, or any animal, may need to be revaccinated.
Titers
Titers are the concentration of antibodies found in the blood. Testing can be done
to determine titer levels, and titers can then aid in determining the level of immunity an
animal has against a disease. Studies have been done using titer testing to try to redefine
the vaccination guidelines in animals (Burr, 2006). The issue with this is that
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uncontrolled variables, such as environment or at home care, as well as different
techniques between veterinary practices make interpreting titers on a large scale difficult.
Therefore, to change the vaccine intervals on a universal level could leave some animals
unprotected if vaccinations were done less frequently (Burr, 2006).
In horses, titer evaluation can be useful for the efficacy of some vaccines such as
rabies, but with others like Eastern/Western encephalomyelitis and West Nile virus, the
titer levels needed for protection are not clear. Additionally, for diseases like equine
influenza and equine herpesvirus which transmit through the respiratory tract, local
immune response is more important than blood antibody levels3. For example, the local
immune response to the influenza vaccine would be the production of virus-specific,
antibody-secreting cells in the respiratory system (Brokstad et al., 1995). These cells are
more important in the defense against influenza than the titer concentration in the blood.
In 2002, the AVMA reported that titer testing in place of vaccinations is generally
unreliable (Moore & Glickman, 2004). This is due to the lack of knowledge on what
levels are actually needed to maintain protection for the animal.
Leptospirosis
Leptospirosis is a bacterial disease that affects both animals and humans. The
bacterium, Leptospira, has over three hundred serovars with Leptospirosis pomona (L.
pomona), being the most common in horses (Fagre et al., 2020). Other serovars

3

The case for (and against) pre-vaccination serology. (2021, May/June). Insight Equine
Edition, 12-14.
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commonly tested for in horses are Leptospirosis grippotyphosa (L. grippotyphosa),
Leptospirosis icterohaemorrhagiae (L. ictero), Leptospirosis canicola (L. canicola),
Leptospirosis hardjo (L. hardjo), and Leptospirosis bratislava (L. bratislava). In equine,
the disease is often transmitted through bodily fluids, contaminated water sources or land,
through the mucus membranes, and through wet or damaged skin. The disease can affect
kidneys, eyes, and pregnant mares causing acute renal failure, abortion, recurrent uveitis,
and many other issues. One vaccination has been approved for use in horses called the
Lepto EQ Innovator®. This vaccination is an inactive or killed vaccine that targets the L.
pomona serovar only. For this vaccine to be effective, it must be administered to horses
not carrying any active or dormant Leptospira bacteria (Divers et al., 2019).
The titer antibody test for Leptospirosis is called the microscopic agglutination
test (MAT). The titer reading for this vaccine can vary widely, and the duration of
immunity is unknown for the vaccination. The Lepto EQ Innovator vaccine is currently
given on an annual basis, with the belief that it provides immunity for at least a year after
administration (Divers et al., 2019). In dogs, an acute infection can be present, and the
MAT test will still read negative. Additionally, no difference is shown between titers
from infected dogs and vaccine induced titers making this test challenging to interpret. It
is said that using MAT titers to determine the vaccines duration of immunity is known to
be inaccurate, with several studies being done that show no relation between the vaccine
titers and actual protection from the disease, although this is based on studies conducted
on dogs (Martin et al., 2014). There may prove to be a difference when a similar study is
conducted on horses.
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Summary
The current belief that leptospirosis titers have little to no effect on the horse’s
immunity to the disease is still not a proven fact. Titer testing is currently the most
accessible and common way to test immunity for Leptospirosis. If a specific titer range
can be found that guarantees immunity the vaccination guidelines could be more
accurately provided. This study will aim to either support or disprove this belief that titers
have little effect on the horse’s immunity to leptospirosis. This will be done through lab
testing on a number of horses.
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Materials and Methods
This project was approved by the Murray State University Institutional Animal
Care and Use Committee with the protocol number 2023-020.
Project 1 Baseline Comparison
Thirty-seven horses, both geldings (n=28) and mares (n=9), between 4 and 26
years old were selected from the Murray State University equine herd. The horses were
used regularly in the program as mounts for classes and team practices. They were
housed in the university barn or in the pastures at the Murray State Equine Center. The
horses received routine management including daily general care, regular vet care as
needed, and annual vaccinations continued during the project.
On day zero of the study, two 10 mL Vacutainers® (BD Vacutainers, Franklin
Lakes, New Jersey, USA) of blood from each horse via the jugular vein. These samples
were placed on ice until being transported to Breathitt Veterinary Center. Samples were
then placed in a Thermo Scientific Multifuge X3 machine where they were spun at 3300
rpms for 5 minutes. This allowed for the serum to be removed from each sample. The
serum was analyzed using the microscopic agglutination test to assess titer concentration
for five leptospirosis serovars: L. pomona, L. ictero, L. grippotyphosa, L. canicola, and L.
hardjo. For the purpose of this study, horses were considered positive if titer
concentrations were at or above 1:200.
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Project 2 Vaccination and Booster
Horses from Project 1 were split into two groups, TRT (vaccinated, n=20) and
CON (not vaccinated, n=17). Horses in the control group remained unvaccinated for the
study and served as a baseline to compare to those vaccinated. The treatment group of
horses were vaccinated by a licensed veterinarian using the Lepto EQ Innovator® (Zoetis
LLC, Parsippany, New Jersey, USA) on day seven. Each horse received the
recommended, intramuscular 1 mL dose of the vaccine on the left side of the neck. All
TRT horses were geldings with no previous history of leptospirosis or related diseases.
Horses were monitored for any adverse reactions following the vaccination.
On day 21, blood was drawn from all 37 horses with the intent to track changes in
TRT horses after vaccination. Samples were collected and processed as described in
Project 1.
According to manufacturer’s guidelines, the Lepto EQ Innovator® requires a 1
mL booster dose three to four weeks following the initial vaccine. On day 28, TRT horses
received the recommended booster vaccination. The vaccine was given on the left side
intramuscularly and was performed by the same veterinarian as in Project 1. All
vaccinated horses were again monitored for any adverse reactions following this
vaccination.
On day 42, blood was drawn again on all 37 horses to evaluate any changes after
the booster vaccination. Samples were gathered and processed as described in Project 1.
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Statistics
Descriptive statistics were used to evaluate the data. Figures were generated using
Microsoft Excel (Version 16.66.1). Reported titer concentration values were graphed, as
were changes over time (no change, increase, or decrease).
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Results and Discussion
No horses exhibited any symptoms related to adverse vaccine reaction or to
leptospirosis infection during this study. There is limited published research on
leptospirosis titers in horses. Cut offs used in different equine studies have ranged from
1:80 to 1:200. The laboratory used to evaluate this data did not evaluate ratios below
1:100. Based on previous publications, this study used a cut off 1:200 to indicate a
positive titer.
Project 1 Baseline Comparison
Overall, results from this study showed that a majority of the Equine Center’s
herd had been exposed to leptospirosis at some point. Using the cut off 1:200 to indicate
a positive titer, 86% of the University’s horses were considered positive for at least one
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serovar (Figure 1). The highest incidence was with L. ictero (83.7% positivity rate).

Horse Name

Figure 1. Number of positive titers in unvaccinated horses for one or more Leptospirosis serovars at day 0
(baseline testing).
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Previous work has shown some differences as well as similarities to the current
study. Kitson-Piggot & Prescott (1987) evaluated 557 horses in Ontario for previous
exposure to leptospirosis and showed a 33.9% positivity for a titer of 1:80 or above. The
most prominent serovar was L. bratislava, with 27.5% of the horses showing a positive
titer of 1:80 (Kitson-Piggot & Prescott, 1987). A similar study by Farge et al. (2020)
evaluated 124 horses from various regions in Colorado. Of the 124 tested, 82% showed a
titer of 1:100 or higher, and 57% showed a titer of 1:200 or higher, for one or more
serovars. The most prominent serovar was again L. bratislava, with 67% having a titer of
1:100 or more, and 37% with a titer of 1:200 or more (Farge et al. 2020). Also, the
current study did not have the opportunity to test for L. bratislava, therefore, no
conclusions could be determined. However, Farge et al. (2020) showed that horses with a
high titer for L. ictero also had high titer for L. pomona, which agreed with this study
(Figure 1). Between these three studies, there were distinctly different results in the titers
of previously unvaccinated horses. It is possible that the leptospirosis bacteria are
becoming more prevalent in the environment, and that fewer horses had been exposed in
1987 as compared to 2020, or even 2022. Another consideration could be geographical
location. The locations of the previous studies have completely different climates
compared to western Kentucky. Ontario and Colorado both experience hard freezes that
may impact the lifespan and concentration of Leptospirosis bacteria in the area, therefore
potentially reducing the seroprevalence. Additionally, horses in both of the previously
published studies were spread out over a larger geographical area than horses in this
study. It is also possible that the University horses were concentrated and exposed to the
leptospirosis bacteria to a greater degree than horses in the other studies.
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Project 2 Vaccination and Booster
Horses in this study received a vaccine that specifically targeted L. pomona. After
the initial vaccination was administered, 100% of the horses in the TRT group showed an
increase in antibody concentration for L. pomona. This resulted in a positive titer for each
horse, which was expected. Leptospirosis pomona titers increased at varying rates,
ranging from 1:200 to 1:25600 (Figure 2).

Titer Concentration

25000
20000
15000
10000
5000
0
Day 0

Day 21

Day 42

Day of Study

Figure 2. Changes in Leptospirosis pomona serovar titer concentration in horses 14 days after first
vaccination (day 21 of the study) and then 14 days after booster vaccination (day 42 of the study). Horses
were vaccinated on day 7.

Following the booster, 45% of the TRT horses had a decrease in their titer
concentration, 30% had an increase, and 25% had no change (Figure 3). A previous study
on the titer response to West Nile virus also showed a decrease in titers after the initial
vaccine but before the booster (Khatibzadeh et al., 2015). This study vaccinated horses on
day 0, tested titers on day 14 and day 46, boostered on day 46, and then tested titers again
on day 74. Results showed that the titer levels had reached a peak at day 14 and then
began to decrease before the booster was administered on day 46. The titer then peaked
again on day 74, and they were higher than the peak before the booster (Khatibzadeh et
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al., 2015). This current study did not test again until after the booster vaccination, so it is
unknown if the titers began decreasing before the booster or after. It is also possible that
the timeframe for titer testing this study did not allow enough time for the titers to fully
rise again after the booster. Further testing in the future may allow for a better
understanding of the physiology behind these unexpected changes.
12
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Figure 3. Changes in Leptospirosis pomona and Leptospirosis ictero titer concentrations after
vaccination (first letter) and after booster (second letter) in treatment group horses. Letters indicated
increase (U), decrease (D), or no change (N).

While the vaccine was targeting L. pomona, it is possible it had some effect on
other serovars. Figure 3 displays the changes for L. pomona and L. ictero after
vaccination and booster (N= no change, D= down/decrease, U= up/increase). With the
vaccination, 95% of the TRT horses also had an increase in the L. ictero serovar (Figure
3), with 100% carrying a positive titer for this serovar. It is interesting to note that L.
ictero titers increased numerically when horses were vaccinated with the L. pomona
vaccine (Figure 3).
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As with L. pomona, many of the horses had a decrease in titer concentration for L.
ictero following the booster vaccination. Similar studies have also shown a correlation
between L. ictero and L. pomona (Farge et al., 2020). Breathitt Veterinary Center staff
confirmed that these two serovars are closely related or work with each other, and
therefore fluctuate similarly (K. Doctorman, personal communication4).
The L. hardjo titers for the TRT horses remained unchanged in all horses except
for one. After receiving the Lepto EQ Innovator®, one gelding in the TRT group
produced a positive titer for L. hardjo. This horse’s titer then dropped below the 1:200 cut
off and was no longer positive after the booster vaccination when tested on day 42
(Figure 4). It is likely that this is unrelated to the vaccination as there is no correlation
between the L. hardjo and L. pomona serovar and the vaccine does not target L. hardjo.
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Figure 4.One horse’s titer concentration changes for each Leptospirosis serovar at day 0, day 21 (14 days after
vaccine), and day 42 (14 days after booster).
4

K. Doctorman. Murray State Breathitt Veterinary Center, Hopkinsville, KY. 2022.

16

For the serovar L. grippotyphosa, TRT horses had a lot of variability in titer
concentration response with no clear pattern in the changes. A majority of the TRT group
saw some increase in their L. grippotyphosa titer levels after the vaccine. There was a
strangely large jump from 1:400 up to 1:3200 in one horse’s L. grippotyphosa titer that
then drastically decreased after the booster (Figure 4). This horse showed similar results
for its L. pomona titer. This horse was the same one noted for different L. hardjo changes.
For L. canicola, the TRT group showed a lot of variation post initial vaccine and
booster titers. A third of the horses had no change at all, even after the vaccine and
booster were administered. Another third had an increase in their titer levels after the
vaccine, but the titer dropped after the booster. The remaining horses had some kind of
change, either up or down after the vaccine and booster. One horse, different from the
one referenced for different changes in L. hardjo and L. grippotyphosa, had the highest
titer at the baseline for L. canicola, but concentrations dropped after the initial
vaccination. By day 42, 50% of the horses ended with a L. canicola titer below 1:200, and
50% had a titer concentration at or above 1:200.
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Conclusion
This study provided seroprevalence data that allowed comparisons to be made
with previously published studies from different locations. In comparison, the Murray
State Equine Center herd showed a higher seroprevalence for Leptospirosis in
unvaccinated horses. Data from this project furthered the available information on
seroprevalence of Leptospirosis in unvaccinated horses. The details on horses’ response
to the vaccination and booster provide data on how horses respond to the vaccine and
how it affected their titers. A titer level that supports immunity was not determined, as it
was not an objective of this study, but this data combined with further research may lead
to a verified titer concentration needed to protect horses against Leptospirosis.
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